162 related articles for article (PubMed ID: 37478617)
21. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
Bai H; Cao D; Yuan F; Sha G; Yang J; Chen J; Wang Y; Zhang Z; Shen K
Gynecol Oncol; 2016 Dec; 143(3):526-531. PubMed ID: 27745918
[TBL] [Abstract][Full Text] [Related]
23. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
[TBL] [Abstract][Full Text] [Related]
24. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
[TBL] [Abstract][Full Text] [Related]
25. Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis.
Kim HS; Kim MA; Lee M; Suh DH; Kim K; No JH; Chung HH; Kim YB; Song YS
Ann Surg Oncol; 2015 Aug; 22(8):2738-45. PubMed ID: 25680339
[TBL] [Abstract][Full Text] [Related]
26. Development of a prediction model for gross residual in high-grade serous ovarian cancer by combining preoperative assessments of abdominal and pelvic metastases and multiparametric MRI.
Lu J; Cai S; Wang F; Wu PY; Pan X; Qiang J; Li H; Zeng M
Acad Radiol; 2023 Sep; 30(9):1823-1831. PubMed ID: 36587996
[TBL] [Abstract][Full Text] [Related]
27. Development and external validation of nomograms for predicting individual survival in patients with ovarian clear cell carcinoma.
Liu X; Lu H; Zhou Y; Long X; Li Q; Zhuang G; Yin X; Di W
Cancer Med; 2023 May; 12(10):11385-11395. PubMed ID: 36971044
[TBL] [Abstract][Full Text] [Related]
28. Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery.
Shuqing L; Zhiling Z
Cancer Med; 2023 Mar; 12(6):6668-6674. PubMed ID: 36416131
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma.
Yamazaki H; Todo Y; Shimada C; Takeshita S; Minobe S; Okamoto K; Yamashiro K; Kato H
J Gynecol Oncol; 2018 Mar; 29(2):e19. PubMed ID: 29400012
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
31. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study.
Cai Y; Yin J; Jin Y; Li Y; Wu M; Yang J; Huang H; Leng J; Pan L
Eur J Surg Oncol; 2020 May; 46(5):876-882. PubMed ID: 31837932
[TBL] [Abstract][Full Text] [Related]
32. Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma.
Shin HY; Yang W; Chay DB; Lee EJ; Chung JY; Kim HS; Kim JH
Mol Oncol; 2021 Apr; 15(4):987-1004. PubMed ID: 33331115
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Sirichaisutdhikorn D; Suprasert P; Khunamornpong S
Asian Pac J Cancer Prev; 2009; 10(6):1041-5. PubMed ID: 20192580
[TBL] [Abstract][Full Text] [Related]
34. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
35. Magnetic resonance imaging findings for discriminating clear cell carcinoma and endometrioid carcinoma of the ovary.
Morioka S; Kawaguchi R; Yamada Y; Iwai K; Yoshimoto C; Kobayashi H
J Ovarian Res; 2019 Feb; 12(1):20. PubMed ID: 30803452
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram.
Li H; Zhang R; Li R; Xia W; Chen X; Zhang J; Cai S; Li Y; Zhao S; Qiang J; Peng W; Gu Y; Gao X
Eur Radiol; 2021 Oct; 31(10):7855-7864. PubMed ID: 33864139
[TBL] [Abstract][Full Text] [Related]
37. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract][Full Text] [Related]
38. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract][Full Text] [Related]
39. Evidence for ethnic and environmental contributions to frequency of ovarian clear cell carcinoma.
Tay SK; Cheong MA
Aust N Z J Obstet Gynaecol; 2014 Jun; 54(3):225-30. PubMed ID: 24888594
[TBL] [Abstract][Full Text] [Related]
40. Current and future strategies for treatment of ovarian clear cell carcinoma.
Ogasawara A; Sato S; Hasegawa K
J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
